effects. However, little is known about the mechanism Possible role of IL-1. Interleukin-1 (IL-1) participates in the of probucol's action on glomerular injury.
In the present brief report, we focus on the action of lar adhesion molecule-1 (ICAM-1) expression in experimental probucol on interleukin-1 (IL-1) secretion and discuss glomerulonephritis. Probucol, an anti-hyperlipidemic agent, the possible mechanism by which probucol may suppress ameliorates some types of glomerulonephritis regardless of serum cholesterol levels, and is also reported to inhibit IL-1 glomerular injury.
release from macrophages in atherosclerotic lesions. However, little is known about the mechanism of this favorable action on glomerular injury. We examined whether or not probucol the development of glomerular lesions in experimental and human glomerulonephritis. Among these cytokines, IL-1 has been known to contribute to the early stage of inflammation in glomerulonephritis. IL-1 has two types A number of studies have demonstrated the beneficial of actions on mesangial cells (Fig. 1) . One important effects of anti-hyperlipidemic therapy on the progression action is to promote cell proliferation. Although IL-1 of renal injury. Inhibition of 3-hydroxy-3-methylglutaryl alone does not promote mesangial cell proliferation, it co-enzyme A (HMG-CoA) reductase, a lipid-lowering synergistically increases proliferation induced by plateagent reported to exhibit the greatest reduction in low let-derived growth factor (PDGF) or basic fibroblast density lipoprotein (LDL) in nephrotic syndrome, amegrowth factor (bFGF) in mesangial cells. We have demliorates proteinuria and glomerulosclerosis in various exonstrated that this synergistic action of IL-1 is mediated perimental models [1] [2] [3] [4] [5] . Probucol, an anti-hyperlipidthrough secretion of group II phospholipase A 2 (PLA 2 ) emic agent originally developed as an antioxidant, also [3] . The other important action of IL-1 is to provoke attenuates proteinuria and glomerulosclerosis in puroleukocyte infiltration, which is mediated, at least in mycin aminonucleoside nephritis (PAN) rats. Recent part, by up-regulating intercellular adhesion molecule-1 studies have shown that probucol reduced the extent of (ICAM-1) expression on mesangial cells. renal injury, as evidenced by proteinuria and glomerular
ROLE OF INTERLEUKIN-1 IN
The interaction between ICAM-1, a member of immulesions, in cholesterol-fed ExHC rats and in passive Heynoglobulin superfamily expressed on a variety of cells mann nephritis [reviewed in 6]. Probucol ameliorates the including mesangial cells, and its counter receptor (lymrenal injury in the absence of significant reduction in phocyte function-associated antigen-1; LFA-1) play a plasma cholesterol levels in these models, suggesting that key role in glomerular leukocyte infiltration in experithe effect produced is not simply due to its hypolipidemic mental models. IL-1 is reported to induce ICAM-1 expression in many types of cells in vitro. Northern blot analysis of ICAM-1 mRNA showed that exogenous IL-1 rat mesangial cells ( Fig. 2A) . Indeed, IL-1-provoked leukocyte adhesion on cultured mesangial cells was inhibited by anti-ICAM-1 antibody [4] . In rat antiglomerular basement membrane (GBM) glomerulonephritis, treatment with IL-1 receptor antagonist (IL-1ra) has been shown to reduce glomerular injury and leukocyte infiltration [5, 6] . This suppression of tissue injury proved to be associated with the reduction of ICAM-1 expression, suggesting that IL-1 participated 
MESANGIAL CELLS
0.05 vs. control; **P Ͻ 0.05 vs. LPS stimulation. (Fig. 2 B and C were reproduced from [2] with permission from Nephrology).
We have recently reported that probucol inhibits ICAM-1 mRNA and ICAM-1 protein expression by suppression of IL-1 activity in cultured rat mesangial cells [2] . Lipopolysaccharide (LPS), a strong stimulant to release IL-1 from mesangial cells, was shown to induce ICAM-1 that LPS and probucol might regulate IL-1 activity at the mRNA expression on mesangial cells (Fig. 2B) . Quiespost-translational level in mesangial cells [2] . In addition, cent mesangial cells were incubated with LPS either in IL-1␤ processing and secretion is stringent and complex. the presence or absence of probucol for 24 hours. LPS IL-1␤ is synthesized as a 31 to 34 kDa precursor (proILincreased ICAM-1 mRNA expression by fivefold and 1␤) and is processed to mature 17 kDa biologically active probucol notably reduced this induction. In addition, form by IL-1␤-converting enzyme (ICE) [9] . Probucol IL-1 receptor antagonist (IL-1ra) suppressed LPS-induced may affect the processing of IL-1 activation. Interest-ICAM-1 mRNA expression on mesangial cells in a doseingly, nitric oxide (NO) was shown to increase IL-1 activdependent manner and 100 ng/ml IL-1ra completely inity in murine macrophages. NO increases the IL-1 activhibited ICAM-1 expression, indicating that the induction ity as well as the amount of IL-1 protein as determined was elicited through the action of secreted IL-1 in an enzyme-linked immunosorbent assay, not by an alterautocrine manner [2] . It is interesting that the changes ation of IL-1 expression nor by modification of IL-1 of ICAM-1 observed at mRNA levels were also conprecursor processing, but by a cyclic GMP-dependent firmed at protein levels within 24 hours after stimulation mechanism [10] . Therefore, LPS may increase IL-1 activby immunoblotting.
ity through the actions of NO, which is a reactive free Probucol has been known to reduce the progression radical, and probucol, an antioxidant, may inhibit the of atherosclerotic lesions. Atherosclerotic lesion results release of IL-1 activity by blocking NO. Further studies from the accumulation of foam cells of monocyte/macroare necessary to clarify the mechanism responsible for phage origin within the arterial intima. IL-1 from these the regulation of IL-1 activity. cells plays an important role in the formation of atherosclerotic lesion. Since probucol is reported to inhibit IL-1 CONCLUSION release from macrophages, probucol may ameliorate athInterleukin-1 and ICAM-1 play a key role in the early erosclerosis both by inhibiting IL-1 release from macrophase of inflammatory reactions in glomerulonephritis. phages and by inhibiting the formation of oxidized LDL,
We demonstrated that probucol inhibited LPS-induced which itself enhances IL-1 release from macrophages ICAM-1 expression in cultured rat mesangial cells, and [8] [9] [10] .
that this inhibition was mediated by blocking the release In this context, we proposed that probucol might supof IL-1 activity from these cells. These results throw press inflammatory processes of glomerulonephritis by light on the therapeutic application of probucol to the inhibiting IL-1 release from mesangial cells. To detersuppression of the inflammatory process of glomerulonemine whether or not probucol would reduce the IL-1 phritis. secretion from mesangial cells and consequently suppress ICAM-1 expression, IL-1 activity in the culture in some cells, whereas it has no effect in others. 93:273-279, 1994 We have recently reported that LPS and probucol 7. Nikolic-Paterson DJ, Lan HY, Hill PA, Vannice JL, Atkins RC: Suppression of experimental glomerulonephritis by the have no effect on IL-1␤ mRNA expression, suggesting
